AVITA Medical (NASDAQ:RCEL - Get Free Report) is projected to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect AVITA Medical to post earnings of ($0.33) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.
AVITA Medical (NASDAQ:RCEL - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.14). The firm had revenue of $18.41 million for the quarter, compared to analyst estimates of $18.40 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ:RCEL opened at $10.22 on Thursday. The company has a 50 day moving average of $10.51 and a 200-day moving average of $10.62. The firm has a market cap of $267.97 million, a P/E ratio of -4.28 and a beta of 1.55. AVITA Medical has a twelve month low of $7.51 and a twelve month high of $18.93. The company has a current ratio of 2.83, a quick ratio of 2.47 and a debt-to-equity ratio of 9.39.
RCEL has been the topic of a number of research reports. D. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of AVITA Medical in a report on Friday, February 14th. Piper Sandler restated a "neutral" rating and set a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a report on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of AVITA Medical in a research report on Tuesday, December 24th. Finally, Lake Street Capital reduced their price target on shares of AVITA Medical from $20.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, AVITA Medical currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.
View Our Latest Stock Analysis on RCEL
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider AVITA Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVITA Medical wasn't on the list.
While AVITA Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.